Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry

American Heart Journal

Volumn 170, Issue 1, 2015, Pages 141-148.e1

  Pokorney, Sean D ^a,b   Simon, Dajuanicia N ^b   Thomas, Laine ^b   Fonarow, Gregg C ^c   Kowey, Peter R ^d   Chang, Paul ^e   Singer, Daniel E ^f   Ansell, Jack ^g   Blanco, Rosalia G ^b   Gersh, Bernard ^h   Mahaffey, Kenneth W ⁱ   Hylek, Elaine M ^j   Go, Alan S ^k   Piccini, Jonathan P ^a,b   Peterson, Eric D ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

^e Janssen Scientific Affairs   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g LENOX HILL HOSPITAL   (United States)

^h MAYO CLINIC   (United States)

ⁱ STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k KAISER PERMANENTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; WARFARIN; ANTICOAGULANT AGENT;

ANTICOAGULATION; ARTICLE; ATRIAL FIBRILLATION; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; COMORBIDITY; CREATININE CLEARANCE; DEMOGRAPHY; DISEASE REGISTRY; ELECTROCARDIOGRAM; FOLLOW UP; HEART FAILURE; INTERNATIONAL NORMALIZED RATIO; LIFE EXPECTANCY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; AGED; COMPLICATION; FEMALE; FRAIL ELDERLY; HEART VALVE REPLACEMENT; HEMORRHAGE; HUMAN; MALE; MIDDLE AGED; REGISTER; RENAL INSUFFICIENCY, CHRONIC; RISK FACTOR; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; STROKE; TIME; TREATMENT OUTCOME; UNITED STATES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; FEMALE; FRAIL ELDERLY; HEART FAILURE; HEART VALVE PROSTHESIS IMPLANTATION; HEMORRHAGE; HUMANS; INTERNATIONAL NORMALIZED RATIO; LOGISTIC MODELS; MALE; MIDDLE AGED; REGISTRIES; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; STROKE; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; WARFARIN;

EID: 84931574254     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2015.03.017     Document Type: Article

References (28)

1. N.J. Patel, A. Deshmukh, and S. Pant Contemporary trends of hospitalization for atrial fibrillation in the United States, 2000 through 2010: implications for healthcare planning Circulation 129 2014 2371 2379
2. P.A. Wolf, R.D. Abbott, and W.B. Kannel Atrial fibrillation: a major contributor to stroke in the elderly: the Framingham Study Arch Intern Med 147 1987 1561
3. P.A. Wolf, T.R. Dawber, and H.E. Thomas Jr. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke Neurology 28 1978 973-977
4. K. Flegel, M. Shipley, and G. Rose Risk of stroke in non-rheumatic atrial fibrillation Lancet 329 1987 526 529
5. T. Wilke, A. Groth, and S. Mueller Oral anticoagulation use by patients with atrial fibrillation in Germany. Adherence to guidelines, causes of anticoagulation under-use and its clinical outcomes, based on claims-data of 183,448 patients Thromb Haemost 107 2012 1053 1065
6. E.M. Hylek, and D.E. Singer Risk factors for intracranial hemorrhage in outpatients taking warfarin Ann Intern Med 120 1994 897 902
7. E.M. Hylek, A.S. Go, and Y. Chang Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation N Engl J Med 349 2003 1019 1026
8. S.J. Connolly, J. Pogue, and J. Eikelboom Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range Circulation 118 2008 2029 2037
9. S.Y. Han, S.T. Palmeri, and S.H. Broderick Quality of anticoagulation with warfarin in patients with nonvalvular atrial fibrillation in the community setting J Electrocardiol 46 2013 45 50
10. J.S. Dlott, R.A. George, and X. Huang National assessment of warfarin anticoagulation therapy for stroke prevention in atrial fibrillation Circulation 129 2014 1407 1414
11. A.J. Rose, E.M. Hylek, and A. Ozonoff Risk-adjusted percent time in therapeutic range as a quality indicator for outpatient oral anticoagulation: results of the Veterans Affairs Study to Improve Anticoagulation (VARIA) Circ Cardiovasc Qual Outcomes 4 2011 22 29
12. J.P. Piccini, E.S. Fraulo, and J.E. Ansell Outcomes registry for better informed treatment of atrial fibrillation: rationale and design of ORBIT-AF Am Heart J 162 2011 606 612
13. F.R. Rosendaal, S.C. Cannegieter, and F.J. van der Meer A method to determine the optimal intensity of oral anticoagulant therapy Thromb Haemost 69 1993 236 239
14. S.L. Zeger, and K.Y. Liang Longitudinal data analysis for discrete and continuous outcomes Biometrics 42 1986 121 130
15. H.D. White, M. Gruber, and J. Feyzi Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V Arch Intern Med 167 2007 239 245
16. L. Wallentin, S. Yusuf, and M.D. Ezekowitz Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial Lancet 376 2010 975 983
17. L. Wallentin, R.D. Lopes, and M. Hanna Apixaban for Reduction in S and Other Thromboembolic Events in Atrial Fibrillation I. Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation Circulation 127 2013 2166 2176
18. J.P. Piccini, A.S. Hellkamp, and Y. Lokhnygina Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial J Am Heart Assoc 3 2014 e000521
19. L.K. Gottlieb, and S. Salem-Schatz Anticoagulation in atrial fibrillation. Does efficacy in clinical trials translate into effectiveness in practice? Arch Intern Med 154 1994 1945 1953
20. R.P. Giugliano, C.T. Ruff, and E. Braunwald Edoxaban versus warfarin in patients with atrial fibrillation N Engl J Med 369 2013 2093 2104
21. A.J. Rose, A. Ozonoff, and R.W. Grant Epidemiology of subtherapeutic anticoagulation in the United States Circ Cardiovasc Qual Outcomes 2 2009 591 597
22. P. Gallego, V. Roldan, and F. Marin SAMe-TT2R2 score, time in therapeutic range, and outcomes in anticoagulated patients with atrial fibrillation Am J Med 127 2014 1083 1088
23. D. Poli, E. Antonucci, and S. Testa A prospective validation of the SAME-TT2R 2 score: how to identify atrial fibrillation patients who will have good anticoagulation control on warfarin Intern Emerg Med 9 2014 443 447
24. P.B. Nielsen, S. Lundbye-Christensen, and L.H. Rasmussen Improvement of anticoagulant treatment using a dynamic decision support algorithm: a Danish Cohort study Thromb Res 133 2014 375 379
25. S.E. Kimmel, B. French, and S.E. Kasner A pharmacogenetic versus a clinical algorithm for warfarin dosing N Engl J Med 369 2013 2283 2293
26. J. Ansell, J. Hollowell, and V. Pengo Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM) J Thromb Thrombolysis 23 2007 83 91
27. S. Mueller, M. Pfannkuche, and G. Breithardt The quality of oral anticoagulation in general practice in patients with atrial fibrillation Eur J Intern Med 25 2014 247 254
28. M. Wieloch, A. Sjalander, and V. Frykman Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA Eur Heart J 32 2011 2282 2289